Automated multidimensional deep learning platform for referable diabetic retinopathy detection: a multicentre, retrospective study

Guihua Zhang, Jian-Wei Lin, Ji Wang, Jie Ji, Ling-Ping Cen, Weiqi Chen, Peiwen Xie, Yi Zheng, Yongqun Xiong, Hanfu Wu, Dongjie Li, Tsz Kin Ng, Chi Pui Pang, Mingzhi Zhang

ABSTRACT

Objective To develop and validate a real-world screening, guideline-based deep learning (DL) system for referable diabetic retinopathy (DR) detection.

Design This is a multicentre platform development study based on retrospective, cross-sectional data sets. Images were labelled by two-level certificated graders as the ground truth. According to the UK DR screening guideline, a DL model based on colour retinal images with five-dimensional classifiers, namely image quality, retinopathy, maculopathy gradability, maculopathy and photocoagulation, was developed. Referable decisions were generated by integrating the output of all classifiers and reported at the image, eye and patient level. The performance of the DL was compared with DR experts.

Setting DR screening programmes from three hospitals and the Lifeline Express Diabetic Retinopathy Screening Program in China.

Participants 83 465 images of 39 836 eyes from 21 716 patients were annotated, of which 53 211 images were used as the development set and 30 254 images were used as the external validation set, split based on centre and period.

Main outcomes Accuracy, F1 score, sensitivity, specificity, area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), Cohen’s unweighted κ and Gwet’s AC1 were calculated to evaluate the performance of the DL algorithm.

Results In the external validation set, the five classifiers achieved an accuracy of 0.915–0.980, F1 score of 0.682–0.966, sensitivity of 0.917–0.978, specificity of 0.907–0.981, AUROC of 0.9639–0.9944 and AUPRC of 0.7504–0.9949. Referable DR at three levels was detected with an accuracy of 0.918–0.967, F1 score of 0.822–0.918, sensitivity of 0.970–0.971, specificity of 0.905–0.967, AUROC of 0.9848–0.9931 and AUPRC of 0.9527–0.9760. With reference to the ground truth, the DL system showed comparable performance (Cohen’s κ: 0.86–0.93; Gwet’s AC1: 0.89–0.94) with three DR experts (Cohen’s κ: 0.89–0.96; Gwet’s AC1: 0.91–0.97) in detecting referable lesions.

Conclusions The automatic DL system for detection of referable DR based on the UK guideline could achieve high accuracy in multidimensional classifications. It is suitable for large-scale, real-world DR screening.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ The data set in this study was constructed from multiple centres using different devices for generalisation.
⇒ The five-dimensional classifiers, namely image quality, retinopathy, maculopathy gradability, maculopathy and photocoagulation, were developed according to a real-world approach to diabetic retinopathy screening.
⇒ The deep learning platform can automatically generate three-level (image, eye and patient level) referable diabetic retinopathy decision.
⇒ Evaluation of two dimensions of quality, namely image quality and maculopathy gradability, on images with diverse qualities was given full consideration, which is consistent with screening practices.
⇒ Diabetic macular edema could be misdiagnosed in some cases without stereo images and optical coherence tomography.

INTRODUCTION

Diabetic retinopathy (DR), a common ocular complication with retinal microvascular lesions in patients with diabetes mellitus (DM), is one of the leading causes of irreversible blindness and visual impairment among working-age people worldwide.1 It is estimated that the DM population will increase to approximately 700 million by 2045, with a quarter suffering from DR.2 3 DR screening programmes are an important interventional strategy for early identification of referable DR and allow timely referral and treatment to prevent vision loss due to DR.4 5 Yet huge screening demand from a large number of patients with DM and the limited amount of human resources hinder the popularity and sustainability of screening services.6

Deep learning (DL), a subset of artificial intelligence (AI) powered by recent advances in computation and big data, permits...
multilayer convolutional neural networks to be trained through back propagation techniques to minimise an error function resulting in a classifier output, which works remarkably well in computer vision (image classification tasks).\(^7\) In recent years, multiple DL algorithms for automatic detection of DR have been proposed and have shown high sensitivity and specificity (>90%) in detecting referable DR.\(^8\)\(^\rightarrow\)\(^11\) Throwing light to large-scale DR screening with AI assistance. However, in complex real-world screening scenarios, an appropriate decision for referral is hard based only on a few dimensions of classifications. Various features or conditions should be identified and handled simultaneously, including the image quality of the fundus photos, stage of DR, maculopathy and photocoagulation status.\(^12\)\(^\rightarrow\)\(^14\) Hence, the DL algorithm on multidimensional features for referable DR detection should be developed to identify multiple conditions in the complex real-world DR screening scenarios. Herein, this study aimed to develop a multi-dimensional DL platform for detecting referable DR with five independent classifiers (image quality, retinopathy, maculopathy gradability, maculopathy and photocoagulation) using real-world DR screening data sets. Combined heatmaps were generated to visualise and explain the predicted areas of the referable lesions. The performance of our DL platform was further compared with retinal specialists.

**METHODS**

Informed consent was approved to be waived for this retrospective study using de-identified retinal images for the development of a DL system. This study followed the Standards for Reporting of Diagnostic Accuracy reporting guidelines.

**Data sets**

The images in this study were captured during DR screening programmes using three types of cameras and were collected from three hospitals (Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong (JSIEC; camera: Top-2000, Topcon, Japan); Liuzhou City Red Cross Hospital (Liuzhou; camera: AFC-230, NIDEK, Japan); and the Second Affiliated Hospital of Shantou University Medical College (STU-2nd; camera: Top-2000, Topcon, Japan)) and one event (Lifeline Express Diabetic Retinopathy Screening Program (LEDRSP); cameras: AFC-230, NIDEK, Japan, and Canon CR-DGii, Canon, Japan) from April 2014 to June 2018. Only mydriatic retinal images with two 45° fields (macula-centred and optic disc-centred) were included. Unless coexisting with DR, images presenting other ocular diseases, such as glaucoma and age-related macular degeneration, were excluded. Non-fundus images were also excluded (online supplemental figure 1).

**Patient and public involvement**

Neither participants nor the public were involved in the design and conduct of the present research.

**Labelling and grading**

Based on the English National Health Screening (NHS) Diabetic Eye Screening Programme (online supplemental table 1),\(^14\)\(^\rightarrow\)\(^15\) the retinal images were assessed in four dimensions, namely (1) image quality, (2) retinopathy, (3) maculopathy and (4) photocoagulation status. The labels of the retinal images were annotated according to the following:

- ‘Image quality’ was categorised as Q0 (ungradable quality, defined as an image with >one-third of the area poorly exposed, with artefact or blur which could not be classified confidently even when any DR feature was observed in the rest of the area) and Q1 (gradable quality, with ≤1/3 poor area that the image could be classified with confidence).
- ‘Retinopathy’ was divided into four levels according to severity of lesions: R0 (no DR), R1 (background DR), R2 (preproliferative DR) and R3 (proliferative DR). R0 and R1 were further defined as non-referable retinopathy, while R2 and R3 were defined as referable retinopathy.
- ‘Maculopathy’ was classified as M0 (absence of any M1 features) and M1 (exudate within 1 disc diameter (DD) of the centre of the fovea or any microaneurysm/haemorrhage within 1 DD of the centre of the fovea only if associated with a best corrected visual acuity of ≤6/12). Additionally, due to the limited blur or artefact (less than 1/3 area of the whole image) on the macula, maculopathy might be ungradable. Thus, evaluation of maculopathy gradability should precede classification of maculopathy and the image which could not be graded confidently in terms of maculopathy would be annotated as maculopathy ungradable (Mu).
- ‘Photocoagulation’ was categorised as P0 (image without laser spot or scar) and P1 (image presenting laser spot or scar).

Detailed definitions are shown in online supplemental table 2.

The ground truth labels of the images were obtained from grading of two-level graders. All graders have been trained and certified by the NHS retinal screening for DR (https://www.gregcourses.com). The workflows for grading with clinical information are as follows: (1) images were primarily graded by two junior graders (PX and YZ) independently and the consistent labels were assigned as the ground truth labels; and (2) images with inconsistent labels from primary grading were submitted for final adjudication by a senior retinal ophthalmologist (GZ). The final adjudication was assigned as the ground truth label. Images satisfying the inclusion criteria and annotated by the ground truth labels were filed as the data set. The development set was constructed using images from LEDRSP and JSIEC, and further randomly divided...
into training, validation and test data sets by 75:10:15 ratio at the patient level, while images from Liuzhou and STU-2nd were used as the external validation set.

**DL algorithm development**

The pipeline of the DR screening system is shown in online supplemental figure 2. Briefly, image evaluation was initiated with assessment of image quality, where gradable images were inputted into the main pipeline, whereas ungradable ones were recommended for ‘rephotography’. To construct the main structure of the system, we proposed four-dimensional independent classifiers (retinopathy, maculopathy gradability, maculopathy and photocoagulation) for any given images and each of the classifiers was binary. Three different kinds of neural networks (Google Inception-V3, Xception and Inception-ReNet-V2) were used as the base model and unweighted average was used as the model ensemble method. We also adopted a postprocessing method to integrate all single-dimension results as the image-level referable results, and further integrated the image-level results as the eye-level or patient-level results. The details of the methods are shown in online supplemental method 1.

The t-distributed stochastic neighbour embedding (t-SNE) heatmaps were used to visualise the features extracted by the neural networks. SHAP-CAM heatmap, combining Class Activation Mapping (CAM) and DeepSHAP, was used to highlight the important regions that the neural networks were used for making the predictions (online supplemental method 2).

Various recommendations were automatically generated by the system to respond the classifications of different classifiers: (1) patients with more serious lesions (R2, R3 or M1), defined as ‘referable DR’ by the English NHS Diabetic Eye Screening Programme (online supplemental table 1), were advised for referral in the study, whereas those with R0, R1 or M0 were advised for follow-up; (2) images with ungradable maculopathy were generally advised for rephotography, unless R2 or R3 was detected on the same image, or any referable DR was found in other fields of the same fundus; and (3) any laser spot or scar recognised on the image would remind of ‘photocoagulation therapy once’, suggesting previous consultation with an ophthalmologist. The following is the order of priority of various recommendations: ‘refer previous ophthalmologist’ > ‘referable’ > ‘rephotography’ > ‘follow-up’. Referable decision was automatically generated by the system that the image-level decision was integrated from multiple classifiers, and any dimensional positive prediction of referable lesion would recommend a referable decision. The referable image would further provide referable recommendation at the eye and patient level.

**Statistical analysis**

The performance of the classifiers was evaluated by true negative, false positive, false negative, true positive, F1 score, sensitivity, specificity, area under the receiver

---

Table 1 Summary of the data sets

| Development set | JSIEC | Liuzhou | STU-2nd | Subtotal |
|-----------------|-------|---------|---------|----------|
| **Periods**     | April 2014–June 2018 | June 2016–June 2018 | April 2014–April 2016 | April 2014–June 2018 |
| **Images, n/N (%)** | 83 465/83 465 (100) | 2567/83 465 (3.1) | 52 313/83 465 (60.7) | 53 211/83 465 (63.8) |
| **Eyes, n/N (%)** | 39 836/39 836 (100) | 2241/39 836 (5.6) | 24 299/39 836 (61.0) | 26 540/39 836 (66.6) |
| **Patients with sex available, n/N (%)** | 17 042/21 716 (78.5) | 1804/2051 (88.0) | 8685/13 026 (66.7) | 10 489/15 077 (69.6) |
| **Age, mean (SD), years** | 60.0 (12.9) | 44.6 (18.8) | 65.2 (9.7) | 57.7 (13.9) |

JSIEC, Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong; LEDRSP, Lifeline Express Diabetic Retinopathy Screening Program; Liuzhou, Liuzhou City Red Cross Hospital; STU-2nd, Second Affiliated Hospital of Shantou University Medical College.
Table 2 Performance of the five classifiers of the system

| Classifiers | Data set       | n   | TN  | FP  | FN  | TP  | Accuracy | F1 score | Sensitivity | Specificity | AUROC (95% CI) |
|-------------|----------------|-----|-----|-----|-----|-----|----------|----------|-------------|-------------|----------------|
| Image quality | Training       | 5818| 180 | 1741| 32 145| 0.952| 0.971  | 0.949 | 0.97        | 0.9882 (0.9874 to 0.9891) |
|             | Validation     | 804 | 64  | 231 | 4165| 0.944| 0.966 | 0.947 | 0.926      | 0.9812 (0.9780 to 0.9844) |
|             | Test           | 1095| 103 | 418 | 6447| 0.935| 0.961 | 0.939 | 0.914      | 0.9768 (0.9737 to 0.9798) |
|             | External validation | 4706| 243 | 1429| 23 876| 0.945| 0.966 | 0.944 | 0.951      | 0.9751 (0.9732 to 0.9770) |
| Retinopathy | Training       | 30118| 544 | 9   | 3215| 0.984| 0.921 | 0.997 | 0.982      | 0.9992 (0.9991 to 0.9994) |
|             | Validation     | 3916| 107 | 15  | 358| 0.972| 0.854 | 0.96  | 0.973      | 0.9956 (0.9941 to 0.9970) |
|             | Test           | 6031| 178 | 16  | 640| 0.972| 0.868 | 0.976 | 0.971      | 0.9962 (0.9951 to 0.9972) |
|             | External validation | 21609| 784 | 65  | 2847| 0.966| 0.87  | 0.978 | 0.965      | 0.9944 (0.9936 to 0.9952) |
| Maculopathy gradability | Training | 5068| 148 | 1269| 27 401| 0.958| 0.975 | 0.956 | 0.972      | 0.9934 (0.9928 to 0.9940) |
|             | Validation     | 617 | 43  | 174 | 3562| 0.951| 0.97  | 0.953 | 0.935      | 0.9896 (0.9873 to 0.9918) |
|             | Test           | 970 | 49  | 302 | 5544| 0.949| 0.969 | 0.948 | 0.952      | 0.9890 (0.9871 to 0.9910) |
|             | External validation | 4374| 451 | 1704| 18 776| 0.915| 0.946 | 0.917 | 0.907      | 0.9639 (0.9617 to 0.9660) |
| Maculopathy | Training       | 24301| 470 | 170 | 3729| 0.978| 0.921 | 0.956 | 0.981      | 0.9962 (0.9957 to 0.9967) |
|             | Validation     | 3186| 104 | 29  | 417| 0.964| 0.862 | 0.935 | 0.968      | 0.9906 (0.9864 to 0.9948) |
|             | Test           | 4900| 130 | 61  | 755| 0.967| 0.888 | 0.925 | 0.974      | 0.9928 (0.9912 to 0.9944) |
|             | External validation | 16987| 572 | 150 | 2771| 0.965| 0.885 | 0.949 | 0.967      | 0.9904 (0.9888 to 0.9919) |
| Photocoagulation | Training | 32526| 105 | 0   | 1255| 0.997| 0.96  | 1.000 | 0.997      | 1.0000 (0.9999 to 1.0000) |
|             | Validation     | 4252| 27  | 5   | 112| 0.993| 0.875 | 0.957 | 0.994      | 0.9924 (0.9794 to 1.0000) |
|             | Test           | 6589| 33  | 8   | 235| 0.994| 0.92  | 0.967 | 0.995      | 0.9979 (0.9958 to 1.0000) |
|             | External validation | 24277| 467 | 29  | 532| 0.98 | 0.682 | 0.948 | 0.981      | 0.9904 (0.9869 to 0.9940) |
| Referable DR* | Training      | 23888| 362 | 147 | 4890| 0.983| 0.951 | 0.971 | 0.985      | 0.9980 (0.9977 to 0.9983) |
|             | Validation     | 3138| 89  | 28  | 544| 0.969| 0.903 | 0.951 | 0.972      | 0.9932 (0.9899 to 0.9965) |
|             | Test           | 4838| 114 | 55  | 953| 0.972| 0.919 | 0.945 | 0.977      | 0.9952 (0.9940 to 0.9964) |
|             | External validation | 16667| 575 | 117 | 3859| 0.967| 0.918 | 0.971 | 0.967      | 0.9931 (0.9920 to 0.9942) |
| Eyes        | Training       | 14764| 411 | 110 | 3136| 0.972| 0.923 | 0.966 | 0.973      | 0.9961 (0.9955 to 0.9967) |
|             | Validation     | 1986| 87  | 15  | 342| 0.958| 0.87  | 0.958 | 0.958      | 0.9906 (0.9850 to 0.9961) |
|             | Test           | 2949| 117 | 36  | 608| 0.959| 0.888 | 0.944 | 0.962      | 0.9923 (0.9901 to 0.9946) |
|             | External validation | 9429 | 624 | 59  | 1876| 0.943| 0.846 | 0.97  | 0.938      | 0.9884 (0.9863 to 0.9905) |
| Patients    | Training       | 8415 | 291 | 74  | 2141| 0.967| 0.921 | 0.967 | 0.967      | 0.9956 (0.9949 to 0.9964) |
|             | Validation     | 1138| 64  | 10  | 237| 0.949| 0.865 | 0.96  | 0.947      | 0.9894 (0.9837 to 0.9951) |
|             | Test           | 1669| 80  | 25  | 407| 0.952| 0.886 | 0.942 | 0.954      | 0.9914 (0.9884 to 0.9943) |
|             | External validation | 4683 | 492 | 37  | 1219| 0.918| 0.822 | 0.971 | 0.905      | 0.9848 (0.9819 to 0.9877) |

*By integrating the prediction of referable retinopathy and maculopathy on an image, referable DR decisions were given by the system when any referable lesion was detected, and the accuracies were based on the image, eye and patient levels.

AUROC, area under the receiver operating characteristic curve; DR, diabetic retinopathy; FN, false negative; FP, false positive; TN, true negative; TP, true positive.

Operating characteristic curve (AUROC) with 95% CI and area under the precision-recall curve (AUPRC). The open source package pROC (V.1.14.0; Xavier Robin) was used to calculate two-sided 95% CI with the DeLong method for AUROC. Data were analysed from 1 May 2019 to 12 June 2021.
An extra independent data set of 253 images from JSIEC and STU-2nd between 1 January 2019 and 31 December 2020 was used in the human–machine comparison with three experienced retinal ophthalmologists for further validation. The ground truth labelled by two-level graders was considered as the criterion standard. For the human–system comparison, the consistency between the graders (three experienced retinal ophthalmologists) and the DL system and the criterion standard were calculated by the Cohen’s unweighted $\kappa$ and Gwet’s AC1. Both of them were further graded using the following scale: 0.2 or less was considered slight agreement, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as strong and 0.81–1.0 as near-complete agreement.

RESULTS
A total of 85 977 retinal images were collected and 2512 (2.9%) were excluded due to a non-fundus view or diseases other than DR, which would reduce the classification performance of the DL system if included in the data sets. Subsequently, a total of 83 465 images of 39 836 eyes from 21 716 patients (mean age of 20 150 patients with available age: 60.0±12.9 years; 7493 of 17 042 (44.0%) from 21 716 patients (mean age of 20 150 patients with available age: 60.0±12.9 years) were eventually annotated and included in the data sets. The development set compiled from JSIEC and LEDRSP included 53 211 images (63.8% of 83 465), and the external test set from Liuzhou and STU-2nd included 30 254 images (36.2%). The distribution of the data is shown in table 1 and online supplemental table 3.

System performance
For the test set at the image level, the performance of all classifiers achieved an accuracy of 0.935–0.994, F1 score of 0.868–0.969, sensitivity of 0.925–0.976, specificity of 0.914–0.995, AUROC from 0.9768 (95% CI 0.9737 to 0.9798) to 0.9979 (95% CI 0.9958 to 1.0000) and AUPRC of 0.9578–0.9981 (table 2, figure 1 and online supplemental figures 3 and 4). The retinopathy classifier achieved an accuracy of 0.972, F1 score of 0.868, sensitivity of 0.976, specificity of 0.971, AUROC of 0.9962 (95% CI 0.9951 to 0.9972) and AUPRC of 0.9687, whereas the maculopathy classifier achieved an accuracy of 0.967, F1 score of 0.888, sensitivity of 0.925, specificity of 0.974, AUROC of 0.9928 (95% CI 0.9912 to 0.9944) and AUPRC of 0.9578.

For the external validation set at the image level, the performance of all classifiers achieved an accuracy of 0.915–0.980, F1 score of 0.682–0.966, sensitivity of 0.917–0.978, specificity of 0.907–0.981, AUROC from 0.9639 (95% CI 0.9617 to 0.9660) to 0.9944 (95% CI 0.9936 to 0.9952) and AUPRC of 0.7504–0.9949 (table 2, figure 1 and online supplemental figures 3 and 4). The retinopathy classifier achieved an accuracy of 0.966, F1 score of 0.870, sensitivity of 0.978, specificity of 0.965, AUROC of 0.9944 (95% CI 0.9936 to 0.9952) and AUPRC of 0.9617, whereas the maculopathy classifier achieved an accuracy of 0.965, F1 score of 0.885, sensitivity of 0.949, specificity of 0.967, AUROC of 0.9904 (95% CI 0.9888 to 0.9919) and AUPRC of 0.9551.

The performance of the three-level (image, eye and patient level) referable DR detection achieved an accuracy of 0.952–0.972, F1 score of 0.886–0.919, sensitivity of 0.942–0.945, specificity of 0.954–0.977, AUROC from 0.9914 (95% CI 0.9884 to 0.9943) to 0.9952 (95% CI 0.9940 to 0.9964) and AUPRC of 0.9679–0.9773 in the test set, and an accuracy of 0.918–0.967, F1 score of 0.822–0.918, sensitivity of 0.970–0.971, specificity of 0.905–0.967, AUROC from 0.9848 (95% CI 0.9819 to 0.9877) to 0.9931 (95% CI 0.9920 to 0.9942) and AUPRC of 0.9527–0.9760 in the external validation set (table 2, figure 1 and online supplemental figures 3 and 4).

Visualisation
The t-SNE helped in the reduction of high-dimensional data extraction from the neural network and structure visualisation on a two-dimensional map. Well-identified binary classes of each classifier are shown in online supplemental figure 5.

In the SHAP-CAM heatmap, the predictive referable lesion visualisation not only showed their located domain, but also the shape of the lesions, which were more fine-discriminative than the CAM heatmaps and with less noise than the DeepSHAP (figure 2).

Human–system comparison
Further validation was conducted on the detection of referable DR lesions between our DL algorithm and three experienced retinal ophthalmologists. Higher sensitivity was found for the DL algorithm (1.000 in retinopathy, 0.949 in maculopathy and 0.953 in referable DR) as compared with that of the retinal ophthalmologists (average (range): 0.935 (0.910–0.970) in referable retinopathy, 0.936 (0.910–0.949) in referable maculopathy and 0.933 (0.918–0.953) in referable DR; table 3). Confusion matrices showed near-complete agreement (Cohen’s $\kappa$: 0.86–0.93; Gwet’s AC1: 0.89–0.94) between the DL algorithm and the ground truth label (online supplemental figure 6), which was comparable with the retinal ophthalmologists (Cohen’s $\kappa$: 0.89–0.96; Gwet’s AC1: 0.91–0.97).

False prediction analysis
The false predictions in the external validation set were analysed by visualisation of heatmaps. Most of the false positives were due to the non-referable DR lesions, including the background DR predicted as referable retinopathy (646 of 784, 82.4%) and the haemorrhage/microaneurysm in the macula with best corrected visual acuity >0.5 as referable maculopathy (178 of 572, 31.1%). Meanwhile, the artefacts were the common interference factor in false positive classifications (7.4% in referable retinopathy and 20.6% in referable maculopathy). Limited blurred images were observed in the false negative predictions for both referable lesions (online supplemental table 4).
DISCUSSION

In this study, we developed a multidimensional DL platform for DR screening based on a real-world screening guideline. Our results demonstrated that (1) the five-dimensional classifiers (image quality, retinopathy, maculopathy gradability, maculopathy and photocoagulation) achieved high accuracy in each classification; (2) a three-level referable DR decision (image, eye and patient level) could be automatically generated by the DL platform; and (3) visualisation by the SHAP-CAM heatmaps provided the explainability for the referable lesion prediction from the platform.

In this study, multiple dimensional classifications were based on the NHS DR classification guideline (NHSDRCG) rather than the International Clinical Diabetic Retinopathy Severity Scale (ICDRSS). In
previous studies, referable DR was defined as moderate and worse DR and diabetic macular edema (DME) or both, where patients with retinopathy that is more severe than mild (defined as the presence of microaneurysms only) would be referred to ophthalmologists. Yet there is still no effective management currently available for patients with an early stage of DR. These patients could only be monitored annually, but not referred to retinal specialists. Over-referral could result when adopting the clinical criteria for referable DR screening, increasing the workload on eye care services and the financial burden associated with the DR screening programmes. The ICDRSS is based on the clinical fundus examination of each quadrant. However, only one or two 45° fields of retinal images were taken for DR grading during the DR screening programme. This would lead

Figure 2  Visualisation by the SHAP-CAM heatmap technique for referable DR lesions. The original images are displayed in the first column, the combined heatmaps generated by SHAP-CAM are shown in the last column, and the heatmaps by CAM and DeepSHAP are shown in the second and third columns for comparison, respectively. (A) Vitreous haemorrhage located on the temporal-superior retina of the original image with the centred macula, suggesting the R3 degree of DR. The CAM heatmap showed a rough location as a wide red-cyan area for the lesion, while the DeepSHAP heatmap demonstrated dispersed dots with some irrelevant noises. The SHAP-CAM heatmap retained an light pink background area, with similar size as that of CAM, and depicted a deeper red clear lesion, same as that of DeepSHAP, in the background. The residue area was masked by CAM as white to reduce inference of redundant information. (B) Retinopathy of R2, including venous beading, intraretinal microvascular abnormality and multiple blot haemorrhages, located around the optic disc on original images. The CAM heatmap showed a rough area for detection, whereas the DeepSHAP heatmap indicated the optic disc as a lesion. For the SHAP-CAM heatmap, all key lesions are depicted in the accurate light pink area without involving the optic disc and macula. (C) The original image showed a referable maculopathy with multiple exudates involving the centre of the fovea. The SHAP-CAM heatmap accurately predicted the shape/outline of the lesions in the macula area, whereas CAM only visualised the lesions by a wide red-cyan circle area and the DeepSHAP showed several light noises out of the macula. DR, diabetic retinopathy.
to inaccurate classification of DR or confuse the graders when the grading is based only on one or two fundus photos. In contrast, the NHSDRCG was specially developed for DR screening and has been used for years in different national DR screening programmes, including the Lifeline Express DR programme in China. For the NHSDRCG, the classification is based on multidimensional features of DR lesions, rather than on the most severe DR lesion. Moreover, our system could provide a referable decision at the eye-level by integrating all image-level decisions of one eye, as well as provide the patient-level decision by combining the results of the two eyes. Multiple DL algorithms have been developed to detect referable or vision-threatening DR, with robust performance in previous studies. Although these studies achieved high accuracy, they were designed predominately focusing on a general classification of referable DR. In daily DR screening practice, complex conditions can be found and need to be handled. The NHSDRCG should be more suitable to support the development of a multidimensional system.

The two dimensions of quality evaluation in our system, namely image quality and maculopathy gradability, are more consistent with screening practices. First, when the fundus photos are sent to the reading centre, the image quality evaluation should precede the classification of severity of DR. Poor image quality could be due to the opacity of the refractive media, artefacts, poor contrast, defocus or small pupil. Previous studies assigned these ungradable pictures to referable DR, which can cause unnecessary worries to patients and confuse the graders on their judgement of referable DR or rephotography. Second, maculopathy gradability should be evaluated before grading the maculopathy. Although some fundus image qualities meet the gradable criteria, the macular area might not be seen due to blur or opacity in the area. Third, our platform could provide the grading outcome of maculopathy alone instead of combining the results of retinopathy and maculopathy. Therefore, we could obtain the basis of referral suggestion, caused by retinopathy or by maculopathy. Since DME could now be treated in most primary medical units or hospitals with antivascular endothelial growth factor, referral to senior special hospitals to receive vitrectomy or photocoagulation therapy might not be necessary.

Photocoagulation status on the retinal images received attention by the NHSDRCG. Its corresponding model was also established in our system, which could judge whether patients have ever received photocoagulation therapy by detecting laser spots on the fundus photos. Laser spots indicate patients have received photocoagulation therapy before screening and the treatment suggested to these patients would be different from other cases.

The SHAP-CAM heatmap highlights the predictive referable DR lesions on retinal fundus pictures. Generally, CAM could indicate the proper size but a less precise domain for lesion identification. In contrast, DeepSHAP could depict specific fine lesions, but more dispersed. The combination of the two techniques can provide a heatmap of lesions in specific domains, meeting the

**Table 3** Performance comparison between the system and three DR experts

| Dimension          | Reader   | n | TN | FP | FN | TP | Accuracy | F1 score | Sensitivity | Specificity | AUROC (95% CI) |
|--------------------|----------|---|----|----|----|----|----------|----------|-------------|-------------|----------------|
| Referable retinopathy | Expert 1 | 181 | 4  | 5  | 62 | 0.964 | 0.932 | 0.925 | 0.978 | NA |
|                    | Expert 2 | 181 | 4  | 6  | 61 | 0.960 | 0.924 | 0.910 | 0.978 | NA |
|                    | Expert 3 | 183 | 2  | 2  | 65 | 0.984 | 0.97  | 0.970 | 0.989 | NA |
|                    | Experts’ average | NA | NA | NA | NA | 0.970 | 0.942 | 0.935 | 0.982 | NA |
|                    | DLA      | 176 | 9  | 0  | 67 | 0.964 | 0.937 | 1.000 | 0.951 | 0.9958 (0.9916 to 1.0000) |
| Referable maculopathy | Expert 1 | 171 | 3  | 7  | 71 | 0.960 | 0.934 | 0.910 | 0.983 | NA |
|                    | Expert 2 | 167 | 7  | 4  | 74 | 0.956 | 0.931 | 0.949 | 0.960 | NA |
|                    | Expert 3 | 166 | 8  | 4  | 74 | 0.952 | 0.925 | 0.949 | 0.954 | NA |
|                    | Experts’ average | NA | NA | NA | NA | 0.956 | 0.93  | 0.936 | 0.966 | NA |
|                    | DLA      | 163 | 11 | 4  | 74 | 0.940 | 0.908 | 0.949 | 0.937 | 0.9877 (0.9756 to 0.9999) |
| **Referable DR**   | Expert 1 | 164 | 3  | 7  | 78 | 0.960 | 0.94  | 0.918 | 0.982 | NA |
|                    | Expert 2 | 161 | 6  | 6  | 79 | 0.952 | 0.929 | 0.929 | 0.964 | NA |
|                    | Expert 3 | 160 | 7  | 4  | 81 | 0.956 | 0.936 | 0.953 | 0.958 | NA |
|                    | Experts’ average | NA | NA | NA | NA | 0.956 | 0.935 | 0.933 | 0.968 | NA |
|                    | DLA      | 163 | 4  | 4  | 81 | 0.968 | 0.953 | 0.953 | 0.976 | 0.9909 (0.9809 to 1.0000) |

NA, not applicable.

*By integrating the prediction of referable retinopathy and maculopathy on an image, referable DR decisions were given by the system when any referable lesion is detected.

AUROC, area under the receiver operating characteristic curve; DLA, deep learning algorithm; DR, diabetic retinopathy; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
requirement for distinguishing maculopathy from retinopathy. These visualisations provide explainability and improve the accuracy of and confidence in DR grading.14,35

Limitations
There were several limitations to this study. First, similar to other studies, DME was graded on non-stereoscopic images according to the presence of hard exudate, microaneurysm or haemorrhage in the macular area. This could be misdiagnosed in some cases without stereoscopic images and optical coherence tomography.36 Second, the lesions, which could be tiny or less frequent, such as intraretinal microvascular abnormality and vein beading, might not be detected well on the images. More data presenting these lesions need to be trained if fine-grained classification than basic screening is required. Third, only two classes (referable and non-referable) and relevant indicators were adopted in the study. Besides, limited by the retrospective data with some missing information, stratified analysis of the classification performance of the DL system based on age, duration of diabetes and various devices, which could influence image quality, was not conducted. A prospective study of multiclass classification (ie, DR 0–5) and multifactor analyses could be carried out in the future. Additional indicators suitable for multiclass classification (ie, weighted kappa) could also be applied.

CONCLUSIONS
This study demonstrated that our DL platform based on a real-world DR screening guideline achieved high sensitivity and specificity with multidimensional classifiers, indicating that AI tools could assist in large-scale screening of referable DR in primary medical units.

Contributors
GZ and MZ proposed and designed the study. GZ, JJ, J-WL, WC, PX, YZ, YX, HW and DL collected the data and/or executed the research. GZ, J-WL and JW analysed the data. GZ, JW, J-WL, JJ and TKN prepared the manuscript. L-PC and CPP gave critical revision. MZ is responsible for the overall content as guarantor.

Funding
This work was supported by the Shantou Medical Health, Science and Technology Project Fund (project code: 190716155262406) and the Grant for Key Disciplinary Project of Clinical Medicine under the Guangdong High-Level University Development Program, China. The funding bodies were not involved in the study, including in the collection, analysis and interpretation of data and in writing the manuscript.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not required.

Ethics approval
This study was approved by the Human Medical Ethics Committee of the Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong (EC201906123(P)-P10), which is in accordance with the Declaration of Helsinki.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request. Both the main text and supplementary materials are published.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Ji Wang http://orcid.org/0000-0001-6997-3837
Weij Chen http://orcid.org/0000-0003-2852-8192
Tsz Kin Ng http://orcid.org/0000-0001-7863-7229
Mingzhi Zhang http://orcid.org/0000-0001-9032-7274

REFERENCES
1 Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. Lancet Glob Health 2017;5:e1221–34.
2 Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 2019;157:107843.
3 Teo ZL, Tham Y-C, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 2021;128:1580–91.
4 Bachmann MO, Nelson SJ. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. J Epidemiol Community Health 1998;52:45–52.
5 Wormald R, Courtney P. Prevention of blindness by screening for diabetic retinopathy. BMJ 1989;299:1528.
6 Wang LZ, Cheung CY, Tapp RJ, et al. Availability and variability in guidelines on diabetic retinopathy screening in Chinese countries. Br J Ophthalmol 2017;101:1352–60.
7 LeCun Y, Bengio Y, Hinton G. Deep learning. Nature 2015;521:436–44.
8 Gulshan V, Peng L, Coram M, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 2016;316:2402.
9 Ting DSW, Cheung CYL, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. JAMA 2017;318:2211–23.
10 Li Z, Keel S, Liu C, et al. An automated grading system for detection of vision-threatening referable diabetic retinopathy on the basis of color fundus photographs. Diabetes Care 2018;41:2509–16.
11 Cen L-P, Ji J, Lin J-W, et al. Automatic detection of 39 fundus diseases and conditions in retinal photographs using deep neural networks. Nat Commun 2021;12:4828.
12 Zhang G, Chen H, Chen W, et al. Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study. Br J Ophthalmol 2017;101:1591–5.
13 Lian JX, Gangwani RA, McGhee SM, et al. Systematic screening for diabetic retinopathy (DR) in Hong Kong: prevalence of DR and visual impairment among diabetic population. Br J Ophthalmol 2016;100:151–5.
14 Harding S, Greenwood R, Aldington S, et al. Grading and disease management in national screening for diabetic retinopathy in England and Wales. Diabet Med 2003;20:965–71.
15 Scanlon PH. The English national screening programme for diabetic retinopathy 2003-2016. Acta Diabetol 2017;54:515–25.
16 Zhou B, Khosla A, Ladepriza A. Learning deep features for discriminative localization, 2015. Available: https://arxiv.org/abs/1512.04150 [Accessed 27 Feb 2021].
17 Selvaraju RR, Cogswell M, Das A. Grad-CAM: visual explanations from deep networks via gradient-based localization, 2016. Available: https://arxiv.org/abs/1610.02391 [Accessed 5 Apr 2020].
18 Lundberg S, Lee S-I. A unified approach to interpreting model predictions, 2017. Available: https://arxiv.org/abs/1705.07874 [Accessed 3 Jan 2020].

Zhang G, et al. BMJ Open 2022;12:e060155. doi:10.1136/bmjopen-2021-060155

Open access
19 Saito T, Rehmsmeier M. The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets. PLoS One 2015;10:e0118432.
20 Wongpakaran N, Wongpakaran T, Wedding D, et al. A comparison of Cohen’s kappa and Gwet’s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med Res Methodol 2013;13:61.
21 Methods and applications of statistics in clinical trials, Volume 2: planning, analysis, and inferential methods. Hoboken, New Jersey. John Wiley & Sons, Inc 2014.
22 Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 1991;98:823–33.
23 Scanlon PH. Screening intervals for diabetic retinopathy and implications for care. Curr Diab Rep 2017;17:96.
24 Group ETDRSR. Fundus photographic risk factors for progression of diabetic retinopathy. Ophthalmology 1991;98:823–33.
25 Zheng Y, Lamoureux EL, Lavanya R, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. Ophthalmology 2012;119:2119–24.
26 Pandey R, Morgan MM, Murphy C, et al. Irish national diabetic RetinaScreen programme: report on five rounds of retinopathy screening and screen-positive referrals. (INDEAR study report No. 1). Br J Ophthalmol 2022;106:409–14.
27 Scanlon PH, Malhotra R, Thomas G, et al. The effectiveness of screening for diabetic retinopathy by digital imaging photography and technician ophthalmoscopy. Diabet Med 2003;20:467–74.
28 Gangeya R, Leng T. Automated identification of diabetic retinopathy using deep learning. Ophthalmology 2017;124:962–9.
29 Rêgo S, Dutra-Medeiros M, Soares F, et al. Screening for diabetic retinopathy using an automated diagnostic system based on deep learning: diagnostic accuracy assessment. Ophthalmologica 2021;244:250–7.
30 Wang Y, Yu M, Hu B, et al. Deep learning-based detection and stage grading for optimising diagnosis of diabetic retinopathy. Diabetes Metab Res Rev 2021;37:e3445.
31 Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193–203.
32 Patrao NV, Antao S, Egan C, et al. Real-World outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National health service setting. Am J Ophthalmol 2016;172:51–7.
33 Wang J, Ji J, Zhang M, et al. Automated explainable multidimensional deep learning platform of retinal images for retinopathy of prematurity screening. JAMA Netw Open 2021;4:e218758.
34 Keel S, Wu J, Lee PY. Visualizing deep learning models for the detection of referable diabetic retinopathy and glaucoma. JAMA Ophthalmol 2018.
35 Sayres R, Taly A, Rahimy E, et al. Using a deep learning algorithm and integrated gradients explanation to assist grading for diabetic retinopathy. Ophthalmology 2019;126:552–64.
36 Wong RL, Tsang CW, Wong DS, et al. Are we making good use of our public resources? the false-positive rate of screening by fundus photography for diabetic macular oedema. Hong Kong Med J 2017;23:356–64.